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BY-NC-ND license (http://creativecomAbstract Cytomegalovirus (CMV) colitis usually occurs in immunocompromised patients with
human immunodeficiency virus infection, organ transplantation, and malignancy receiving
chemotherapy or ulcerative colitis receiving immunosuppressive agents. However, CMV colitis
is increasingly recognized in immunocompetent hosts. Notably, CMV colitis coexisting with
Clostridium difficile infection (CDI) in apparently healthy individuals has been published in
recent years, which could result in high morbidity and mortality. CMV colitis is a rare but
possible differential diagnosis in immunocompetent patients with abdominal pain, watery,
or especially bloody diarrhea, which could be refractory to standard treatment for CDI. As a
characteristic of CDI, however, pseudomembranous colitis may be only caused by CMV infec-
tion. Real-time CMV-polymerase chain reaction (PCR) for blood and stool samples may be a
useful and noninvasive diagnostic strategy to identify CMV infection when treatment of CDI
eventually fails to show significant benefits. Quantitative CMV-PCR in mucosal biopsies may in-
crease the diagnostic yield of traditional histopathology. CMV colitis is potentially life-
threatening if severe complications occur, such as sepsis secondary to colitis, massive colo-
rectal bleeding, toxic megacolon, and colonic perforation, so that may necessitate pre-
emptive antiviral treatment for those who are positive for CMV-PCR in blood and/or stool sam-
ples while pending histological diagnosis.
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830 K.-S. Chan et al.BackgroundCytomegalovirus (CMV) is a highly prevalent and globally
distributed virus. CMV infection in healthy adults is usually
asymptomatic or causes a mildly infectious mononucleosis-
like syndrome. CMV then usually becomes dormant until
reactivation in patients with severely immunocompromised
status, who may potentially develop invasive CMV disease
with a wide range of manifestations, most commonly
colorectal infection with hemorrhagic ulceration. Two
coexistent entitiesdCMV colitis and Clostridium difficile
colitisdhave usually been reported among immunocom-
promised patients, who have human immunodeficiency
virus infection, organ transplantation, hematologic malig-
nancy, solitary organ cancer, or inflammatory bowel disease
receiving immunosuppressive agents.1e9 For example,
Florescu et al8 reviewed nine patients who developed C.
difficile and CMV colitis; among them, eight patients were
immunocompromised: four transplant recipients, two
oncology patients, one patient with advanced acquired
immunodeficiency syndrome, and one on an immunosup-
pressive regimen for severe ulcerative colitis. Besides, CMV
colitis can mimic or present as pseudomembranous colitis in
immunocompromised patients.10e14
CMV gastrointestinal disease rarely occurs in immuno-
competent patients and could resolve completely without
the use of antiviral drugs, if the immunity is obtained.15 In
addition, CMV colitis is increasingly recognized in appar-
ently immunocompetent patients in some immunomodu-
lating conditions, such as elderly, pregnancy, chronic renal
failure, coronary artery disease, ischemic heart disease,
congestive heart failure, diabetes mellitus, steroid use,
blood transfusion, and prolonged stay in the intensive care
units (ICUs).15e28 However, CMV colitis in these patients has
often been neglected by clinical physicians.28 Therefore,
this review article will mainly focus on English literature of
CMV colitis coexisting, following, or followed by C. difficile
colitis among previously healthy or apparently immuno-
competent adult patients. We will also review those cases
of CMV colitis presenting as a sole cause of pseudomem-
branous colitis without C. difficile infection (CDI).
Epidemiology of CMV colitis in
immunocompetent patients
One systemic review identified only 91 immunocompetent
patients with gastrointestinal CMV infections for the period
of 1950e2007.25 Another literature review from 1980 to
2003 identified 44 immunocompetent patients with CMV
colitis. Among them, spontaneous remission occurred in
31.8%, mostly individuals <55 years old.21 In Korea, 51
immunocompetent patients with CMV colitis, including 11
ICU patients and 17.6% with spontaneous remission, were
diagnosed at a tertiary care university hospital between
January 1995 and February 2014.23 In specific hospital ICU
units, CMV colitis was diagnosed in 14 previously immuno-
competent ICU patients at a teaching hospital in Brazil from
January 2000 to March 2013.27 While in Taiwan, with
intention to diagnosis, CMV colitis was detected in 18 ICU
patients at a teaching hospital from January 2011 through
June 2013.28 Among them, three patients had malignancy.The biopsy-proven diagnosis was made for eight patients.
Other probable cases were diagnosed based on clinical
symptoms with detection of blood CMV DNA plus either
colonoscopic findings or detection of CMV DNA in stool
samples.28 Traditionally, CMV colitis was easily neglected
and underdiagnosed in ICU patients with chronic critical
illness, particularly with chronic renal failure.23,27,28Epidemiology of C. difficile colitis
Diseases caused by C. difficile range from mild diarrhea to
potentially life-threatening pseudomembranous colitis.
CDIs occur primarily in hospitalized patients with risk fac-
tors such as concomitant or recent use of antibiotics.29 The
colonization rate of C. difficile in adult hospitalized pa-
tients shows geographic variation, ranging from 4.4% to
23.2%.30 The hypervirulent C. difficile strains such as the
epidemic clone (027/NAP1/BI) has partly contributed to
change the CDI epidemiology to worldwide dissemination.31
In particular, elderly patients in surgical wards and ICUs are
at significant risk of developing CDI.32 After 2006, a 47%
increase in the rate of CDI was noted in the USA.33 In a
cohort of hospitalized older adults in Michigan, impaired
functional status was an independent risk factor for severe
CDI.34 In one study in Korea between January 2007 and July
2012, 55% of colitis in elderly people in long-term care fa-
cilities was caused by CDI, whereas nonspecific colitis was
most common (63%) in elderly people in local commu-
nities.35 Diagnosis of CDI is based on the identification of C.
difficile toxins A and B in diarrheal stool. First-line antibi-
otics for CDI treatment are metronidazole and vancomy-
cin.36 Fidaxomicin, a macrolide antibiotic, has been shown
to be significantly effective in treating CDI compared with
vancomycin.37 For recurrence and relapse of CDI, rifaximin
and tigecycline have yielded some positive outcomes
against C. difficile.38 Fecal microbiota transplant is an
alternative therapy for CDI that is effective and promising
in multiple CDI recurrences.39Coexisting CMV and C. difficile colitis
A history of cytomegalovirus infection has been recognized
as one of the significant risk factors for C. difficile coloni-
zation.30,40 Adult patients colonized with toxigenic C.
difficile were prone to the subsequent development of C.
difficile-associated diarrhea.30 Critically ill patients and
elderly patients are at an increased risk of developing
diarrheal illness like CDI and CMV colitis. Literature of
coexisting CMV and C. difficile colitis have been reported in
immunocompetent patients, mostly in the years after 2010
(Table 1), implying that effective alerts are increasing to
current physicians. Presenting symptoms of both diseases
included fever, diarrhea, gastrointestinal bleeding, and
abdominal pain, with predominance of severe watery
diarrhea for CD, and bloody stool and occasional massive
bleeding for CMV colitis. Both may cause toxic megacolon
and bowel perforation, leading to a poor prognosis.51
However, we propose that the clinical features of colitis
caused by both etiologies could vary with the following
scenarios (Table 1).
Table 1 The clinical features of cytomegalovirus colitis coexisting, following, or mimicking Clostridium difficile colitis in the
immunocompetent patients.
Case Age/sex Diarrhea Diagnosis modality positive for Time lag
of 2nd
diagnosis
Therapy Outcome Y of
referenceCDI CMV colitis
CMV colitis coexisting CDI with refractory pseudomembranous colitis
1 78/F Bloody Stool toxina Colon biopsyb Immunostainc >3 wk Me,V, Fi,
S, G, TC
Recovery 201241
2 82/M Bloody Stool toxina Colon biopsyb Immunostainc
CMV-PCR(1)d
3 d Me, G, Vg Recovery 201428
3 53 Watery Stool toxina CMV-IgMb
Colon biopsyc
e Me, V, R,
S, G
Recovery 201442
4 63/F Watery Stool toxina CMV-PCR(1)b
Immunostainc
>7 d Me, V, S, G Recovery 201543
CMV colitis coexisting CDI with refractory nonpseudomembranous colitis
5 81/M Bloody Stool toxina Colon biopsyb
CMV-PCR (1)c
e Me, V,
G
Recovery 200944
6 37/F Watery Stool toxina Colon biopsyb
Antigenemiac
>2 wk Me, V, G, Fc Recovery 201345
7 85/M Watery Stool culturea Colon biopsyb immunostainc e Me, V, G Recovery 201446
8 60/F Bloody Stool culturea Immunostainb
CMV-igmc
>10 d Me, no
antiviral
Recovery 201515
9 90/M Bloody Stool toxina Colon biopsyb Immunostainc 14 d M, G Recovery 201547
CMV colitis following successful therapy for CDI
10 83/F Some
blood
Stool culturea Colon biopsyb
CMV-IgMc
d V, G Diede 199248
11 74/F Bloody Stool toxina CMV-PCR (1)b
2nd colonoscopy-immunostainc
3 wk Me, G Diedf 201428
CMV colitis as a cause of pseudomembranous colitis without CDI
12 63/M d Colonoscopya and biopsyb CMV-PCR(1e3)c
Immunostaind
No time lag V, no
antiviral
Diedg 200049
13 29/M Watery Colonoscopic findinga 2nd colonoscopy with biopsyb e Me, G Recovery 201150
14 69/M Watery Colonoscopic findinga CMV-PCR(1e2)b
Immunostainc
9 d Me, V, G Diedh 201428
e Postmortem examination revealed severe pneumonia and inflamed colitis but without CMV inclusion bodies.
f Ganciclovir was delayed to commence 3 weeks after CMV diagnosis but was discontinued due to worsening leukopenia, and thus
failed to give improvement.
g Postmortem examination revealed CMV myocarditis, pneumonitis, and colitis.
h Patient had symptomatic improvement of CMV colitis but died due to other comorbidities.
CDI Z Clostridium difficile infection; CMV Z cytomegalovirus; colon biopsy Z histopathological findings of colonic mucosa with he-
matoxylin and eosin stain; F Z female; Fc Z foscarnet; Fi Z fidaxomicin; G Z ganciclovir; IgM Z immunoglobulin M;
immunostainZ CMV immunohistochemical staining; MZ male; MeZ metronidazole; PCRZ polymerase chain reaction for samples of
(1)Z blood, (2)Z stool, and (3)Z mucosal biopsies; RZ rifaximin; SZ stool microbiota transplant; stool toxinZ Clostridium difficile
toxin assay for stool sample; TC Z total colectomy; V Z vancomycin; Vg Z valganciclovir.
a,b,c,d Sequential order of positive diagnosis modalities.
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CDI with pseudomembranous colitis unresponsive to
metronidazole and vancomycin therapy may need fecal
transplantation to overcome the severe colitis. However,
concomitant CMV colitis may partly contribute the re-
fractory course and necessity simultaneous ganciclovir
therapy to completely resolve the colitis.42 We previously
reported an 82-year-old man who had coexistent CMV and
CDI-associated pseudomembranous colitis (Figure 1).28
Moreover, Kurtz and Morgan41 reported an immunocompe-
tent elderly woman with CDI, which was unresponsive to
metronidazole, vancomycin, fidaxomicin, and stool trans-
plant due to concomitant CMV colitis. We also reported acase of toxic megacolon leading to respiratory failure,
which developed after therapy with metronidazole, van-
comycin, and fecal microbiota transplants for CDI-
associated pseudomembranous colitis. An immunostaining
study was performed on the initial colon mucosal biopsy
and it confirmed concomitant CMV colitis with CDI.43CDI with refractory colorectal ulcers or diffuse
colitis without pseudomembranes
Nonimmunosuppressed patients with prolonged ICU stay
due to chronic critical illness are at a high risk for both CDI
and CMV colitis. Of the two diagnoses, CMV is likely missed
Figure 1. Colonoscopic findings showing: (A) pseudomembranous colitis; (B) colon mucosal biopsy showing enlarged atypical
lymphocytes with eosinophilic inclusion bodies (arrow); and (C) positive for cytomegalovirus immunostaining (arrow). The results of
blood cytomegalovirus-polymerase chain reaction and stool Clostridium toxin assay were both positive.
832 K.-S. Chan et al.more often because a biopsy or immunostaining is required
to confirm the diagnosis, while CDI can be diagnosed based
on noninvasive fecal C. difficile toxin assay.8 Many clini-
cians would only treat CDI for a patient with severe diar-
rhea and positive C. difficile toxin in the stool.
Concomitant CDI and CMV colitis may sometimes mani-
fest with diffuse colitis without pseudomembranes, which
was refractory to first-line antibiotics for CDI
treatment.15,44e47 For example, Harano et al15 reported a
60-year-old immunocompetent woman who presented with
abdominal pain and bloody diarrhea due to colorectal
erosion and ulceration with positive stool isolate of C.
difficile. Administration of metronidazole did not improve
her symptoms. Endoscopic biopsy with immunostaining
revealed CMV colitis. Hung et al46 reported CMV colitis with
the presentation of watery diarrhea and stool culture pos-
itive for C. difficile, but diarrhea persisted despite oral
metronidazole and vancomycin therapy. Chen et al47 pre-
sented a 90-year-old, critically ill, immunocompetent pa-
tient, who had multiple refractory C. difficile-infected
ulcers in the sigmoid colon and biopsy confirmed CMV co-
litis. This scenario was similar to a patient of lower lip
squamous cell carcinoma who had diffuse pancolitis unre-
sponsive to metronidazole, vancomycin enemas, and later
fidaxomicin, even though his stool C. difficile toxin became
negative conversion. At this point, the CMV polymerase
chain reaction (PCR) in his stool and blood were positive,
and pre-emptive therapy with valganciclovir resulted in
rapid clinical response and uneventful recovery.9CMV colitis following successful therapy for CDI
Persistent diarrhea or relapse of intestinal symptoms after
appropriate antimicrobial therapy for CDI may not neces-
sarily indicate ineffective therapy for refractory course of
CDI. Jawad48 reported a patient with diarrhea and her stool
culture was positive for C. difficile. Oral vancomycin
rendered her stool negative but some bloody diarrhea
occurred due to sequential CMV colitis. We previously re-
ported a patient who had a therapeutic response to initial
C. difficileeassociated pseudomembranous colitis but the
symptoms relapsed 3 weeks later due to the emergence of
CMV-associated colon ulceration.28 This scenario might be
related to the reactivation of latent CMV infection inconditions of immunomodulation caused by pseudomem-
branous colitis.
CDI following successful therapy for CMV colitis
This rare scenario was reported in an elderly patient with
adult T-cell leukemia lymphoma, who developed CMV co-
litis on Day 5 of chemotherapy. After 2 weeks of successful
ganciclovir therapy, the patient developed diarrhea again
with CDI-associated pseudomembranous colitis instead of
CMV colitis. At that time, CMV antigenemia and a histologic
study for CMV were negative.2
CMV colitis as a cause of pseudomembranous colitis
without CDI
In addition to manifesting with solitary ulcer, multiple ul-
cers, diffuse colitis, and polypoid lesions, occasionally CMV
colitis may present with pseudomembranes, leading to a
misdiagnosis as CDI-associated pseudomembranous coli-
tis.26,52 This scenario should be considered particularly
when C. difficile toxin assays or cultures are negative.49,50
We previously described a patient who had CMV-associated
pseudomembranous colitis (Figure 2), as the result of the
Clostridium toxin assay was negative and the patient
experienced a poor response to oral metronidazole
therapy.28
Current diagnosis and treatment of CMV colitis
Historically, the diagnostic gold standard for CMV colitis is
the direct histopathological identification of the Cowdry
owl eye inclusion bodies in colonic biopsies or the use of
immunohistochemistry (IHC) staining. Although CMV anti-
genemia and blood CMV-PCR showed low sensitivity (<50%)
for diagnosing CMV colitis, the specificity values were high
(>80%).53 In the presence of significant colon ulcers, how-
ever, the sensitivity of CMV antigenemia or PCR for diag-
nosing CMV colitis rose to 67.3%.53 Real time PCR for CMV
DNA quantification in the blood and stool as well as in the
colonic biopsy is currently considered as a useful diagnostic
tool.54 The accuracy of these diagnostic modalities
compared with the diagnostic gold standard are summa-
rized in Table 2.
Figure 2. Colonoscopic finding is showing colitis with pseudomembranes. The cytomegalovirus-polymerase chain reaction for
blood and stool were positive. The stool Clostridium toxin assay was negative. The histopathological findings were consistent with
pseudomembranous colitis but immunostains confirmed cytomegalovirus colitis (not shown).
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Yoshino et al55 reported that quantitative real-time PCR
(qPCR) for detecting CMV infection in inflamed colonic
mucosa is useful for accurate diagnosis of CMV infection.
Mills et al56 reported that CMV DNA was detected by PCR in
90.9% (30/33) of IHC-positive and 14.5% (8/55) of IHC-
negative mucosal biopsies, respectively. Their study indi-
cated that CMV-PCR in gastrointestinal mucosal biopsies
complements IHC and has the potential to identify addi-
tional patients who may benefit from anti-CMV therapy.
McCoy et al57 further reported that qPCR is highly sensitive
and specific to aid in the early diagnosis of CMV infection on
equivocal gastrointestinal biopsies. The mean value of CMV
DNA load in gastrointestinal biopsies was 3845 copies/mg
total DNA (range, 15e15,500 copies/mg total DNA). How-
ever, the cutoff values for diagnosis of CMV colitis were not
determined.61
It should be highlighted that negative histopathological
findings of small colonic mucosal biopsies could not defini-
tively exclude the diagnosis of CMV colitis. Theoretically,
multiple biopsy specimens from longitudinal ulcers orTable 2 The diagnostic test evaluation of new diagnostic moda
CMV diagnostic modalities Gold standard Sensitivity, %
Antigenemia in UC patients53 Histopathology 47.0
PCR for blood in UC patients53 Histopathology 44.3
Real-time (qPCR) in colon
mucosal biopsies55
Histopathology 100
Real-time (qPCR) in digestive
mucosal biopsies56
Histopathology 90.9
Real-time (qPCR) in digestive
mucosal biopsies57
Histopathology 96.7
PCR for stool58 Histopathology 100
PCR for stool59 PCR in colon
mucosal biopsies
83.3
Real-time (qPCR) for stool60 Histopathology 66.7
CMV Z cytomegalovirus; qPCR Z quantitative polymerase chain reacdiffuse colitis combined with qPCR in mucosal biopsies
could increase the diagnostic yield of CMV colitis, especially
in those patients known for positive CMV-PCR for blood
and/or stool samples.
CMV real-time PCR for blood samples
Quantification of plasma CMV DNA by real-time PCR is a
noninvasive method of aiding diagnosis and can be used to
monitor the treatment of CMV infection in immunocompe-
tent patients.20,62 Concordance between plasma real-time
PCR and the pp65 antigenemia assay was 82.2%.63 Howev-
er, plasma real-time PCR is more sensitive than the anti-
genemia assay for monitoring active CMV infection.63,64
However, blood CMV-PCR stands for CMV reactivation, and
further direct evidences of CMV colitis by other diagnostic
tools are required.
CMV real-time PCR for fecal samples
Michel et al58 first adopted CMV-PCR for stool specimens as
a diagnostic tool for patients with suspected CMV colitis.lities for cytomegalovirus colitis or digestive tract infections.
Specificity, % Positive
predictive value, %
Negative
predictive value, %
81.7 59.1 73.0
87.9 67.3 73.6
50.0 23.5 100
85.5 79.0 94.0
98.7 98.9 96.3
94.1 80.0 100
93.3 83.3 93.3
95.7 80.0 91.8
tion; UC Z ulcerative colitis.
834 K.-S. Chan et al.They concluded that the absence of CMV DNA in stool
samples may prove useful in ruling out CMV-related colitis.
Thereafter, Boom et al65 quantified CMV DNA loads in
clinical fecal specimens to monitor the efficacy of antiviral
treatment. In a small pilot study, the sensitivity, specificity,
and accuracy of the PCR-based stool test for detection of
CMV DNA compared with PCR-based detection of CMV in
mucosal biopsies were 83%, 93%, and 90%, respectively.59
We also found qualitative CMV-PCR for stool samples help-
ful in aiding the diagnosis of CMV colitis.28 In a recent study
from Germany, quantitative CMV real-time PCR in fecal
samples was positive in eight out of 12 patients of CMV
intestinal disease (sensitivity, 67%), and was negative in the
non-CMV group (45/47), indicating a good specificity of
96%.60 Therefore, negative CMV PCR results from fecal
samples cannot exclude CMV intestinal disease, whereas
positive fecal PCR results could facilitate an earlier
detection of ongoing CMV infections and might help to
circumvent invasive biopsy via endoscopy. Otherwise, fecal
PCR may guide a pre-emptive therapy for life-threatening
conditions, such as massive colonic bleeding, when a
conclusive histopathological proof of CMV infection is not
yet available.28Strategy for diagnosis and controversy in treatment
of CMV colitis
The development of abdominal pain, fever, watery diar-
rhea, and bleeding stool in a critically ill patient should
prompt the clinician to consider the diagnosis of CMV and
CDI-associated colitis. Diagnostic strategy could be
designed as follows.
If standard stool pathogens and C. difficile toxin studies
are nondiagnostic, endoscopic evaluation and CMV-PCR for
blood and stool samples should be obtained. Quantitative
CMV-PCR in mucosal biopsies seems to be a useful tool for
diagnosis when combined with blood/stool PCR and
endoscopic findings. In another way, if the results of stool
C. difficile toxin assay are positive, the possibility of
coexistent or sequential CMV colitis should not be
neglected. For those patients with a diagnosis of Clos-
tridium colitis but who are unresponsive or partially
responsive to therapy with metronidazole and/or vanco-
mycin, and especially if CMV-PCR for blood and/or stool
samples was positive, then re-evaluation of the initial
colon mucosal biopsies using qPCR for CMV would be
helpful.
It is possible that complete resolution of colonic ul-
ceration could be spontaneously achieved without use of
antiviral drugs in some immunocompromised or immuno-
competent patients with CMV colitis.15,21,23 However, if
CMV infection is confirmed, ganciclovir therapy should be
initiated without delay in critically ill patients to avoid
severe complications of colorectal massive bleeding and
perforation. Most of the reported cases of CMV colitis
coexisting or following CDI as well as presenting as
pseudomembranous colitis had good clinical outcomes
under appropriate medical therapy (Table 1). If bowel
perforation occurs, prompt surgical resection is
indicated.66Conclusion
Currently, CMV colitis is increasingly recognized in immu-
nocompetent patients, manifesting with symptoms similar
to or consistent with CDI-associated pseudomembranous
colitis. CMV colitis most commonly presents with bloody
stool in chronic status of critically ill patients with immu-
nomodulating comorbidities, whereas C. difficile may pro-
duce severe watery diarrhea in those exposed to broad
spectrum antibiotics. Coexisting CMV in the apparently CDI-
associated colitis could correspond to intractable colo-
rectal symptoms. If CMV-PCR for blood and stool samples
were positive, endoscopic biopsy with immunostaining of
mucosal specimens is a definitive procedure for diagnosing
CMV colitis, even in a case of pseudomembranous colitis or
a case positive for fecal C. difficile toxin assay. In cases of
coexisting CMV and C. difficile colitis, ganciclovir therapy
for CMV colitis in time may circumvent the unnecessary
second-line therapeutic method or fecal transplantation for
CDI, supposing that persistent diarrhea was not due to
treatment failure for C. difficile.Conflicts of interest
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